RT Journal Article
SR Electronic
T1 Predictors and consequences of HIV status disclosure to adolescents living with HIV in Eastern Cape, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21266573
DO 10.1101/2021.11.19.21266573
A1 Edun, Olanrewaju
A1 Shenderovich, Yulia
A1 Zhou, Siyanai
A1 Toska, Elona
A1 Okell, Lucy
A1 Eaton, Jeffrey W
A1 Cluver, Lucie
YR 2021
UL http://medrxiv.org/content/early/2021/11/19/2021.11.19.21266573.abstract
AB Introduction The World Health Organization recommends full disclosure of HIV-positive status to adolescents who acquired HIV perinatally (APHIV) by age 12. However, even among adolescents (aged 10-19) already on antiretroviral therapy (ART), disclosure rates are low. Caregivers often report the child being too young and fear of disclosure worsening adolescents’ mental health as reasons for non-disclosure. Evidence is limited about predictors of disclosure and its association with adherence, viral suppression, and mental health outcomes among adolescents in sub-Saharan Africa.Methods Analyses included three rounds (2014-2018) of data collected among a closed cohort of adolescents living with HIV in Eastern Cape, South Africa. We used logistic regression with respondent random-effects to identify factors associated with disclosure, and assess differences in ART adherence, viral suppression, and mental health symptoms between adolescents by disclosure status. We also explored differences in the change in mental health symptoms and ART adherence between study rounds and disclosure groups with logistic regression.Results 813 APHIV were interviewed at baseline, of whom 769 (94.6%) and 729 (89.7%) were interviewed at the second and third rounds, respectively. The proportion aware of their HIV-positive status increased from 63.1% at the first round to 85.5% by the third round. Older age (adjusted odds ratio (aOR): 1.24; 1.07 – 1.43) and living in an urban location (aOR: 2.76; 1.67 – 4.45) were associated with disclosure between interviews. There was no association between awareness of HIV-positive status and ART adherence, viral suppression, or mental health symptoms among all APHIV interviewed. However, among APHIV not aware of their status at baseline, adherence decreased at the second round among those who were disclosed to (N=131) and increased among those not disclosed to (N=151) (interaction aOR: 0.39; 0.19 – 0.80). There was no significant difference in the change in mental health symptoms between study rounds and disclosure groups.Conclusions Awareness of HIV-positive status was not associated with higher rates of mental health symptoms, or lower rates of viral suppression among adolescents. Disclosure was not associated with worse mental health. These findings support the recommendation for timely disclosure to APHIV, however, adherence support post-disclosure is important.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the UK Research and Innovation Global Challenges Research Fund (UKRI GCRF) Accelerate Hub [ES/S008101/1]; UNICEF Eastern and Southern Africa Office, Nuffield Foundation [CPF/41513]; Evidence for HIV Prevention in Southern Africa, a UKAID programme managed by Mott MacDonald; Janssen Pharmaceutica NV part of the Janssen Pharmaceutical Companies of Johnson & Johnson; and the International AIDS Society through the CIPHER grant (155-Hod; 2018/625-TOS); Claude Leon Foundation (08 559/C); Oak Foundation (R46194/AA001, OFIL-20-057); the John Fell Fund (103/757 and 161/033); the University of Oxfords Economic and Social Research Council Impact Acceleration Account (IAA-MT13-003; 1602-KEA-189; K1311-KEA-004); the Leverhulme Trust (PLP-2014-095); Research England; the European Research Council (ERC) under the European Unions (EU) Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement 313421, the EU's Horizon 2020 research and innovation programme/ERC grant agreement 737476, 771468); the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, and by the Department of Health Social Care through its National Institutes of Health Research (MR/R022372/1|), Oxford University Clarendon-Green Templeton College Scholarship, the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA), the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434, the content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. OE was funded by Wellcome Trust (reference 222376/Z/21/Z) and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. YS was supported by DECIPHer and the Wolfson Centre for Young Peoples Mental Health. DECIPHer is funded by Welsh Government through Health and Care Research Wales. The Wolfson Centre for Young Peoples Mental Health has been established with support from the Wolfson Foundation. JWE was supported by the National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number R01AI152721. Funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was granted by the Institutional Review Boards at the Universities of Cape Town (CSSR 2013/4) and Oxford (SSD/CUREC2/12-21). Provincial approval was obtained from the Eastern Cape Departments of Education and Health and participating health facilities to conduct the study and access medical records. Written informed consent for the interviews and to access clinical records was obtained from participants and their primary caregivers. Ethical approval for the secondary analyses of study data was obtained from the Imperial College Research Governance and Integrity Team (20IC6451).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors